Amarin Corporation plc (AMRN)

Market Cap	331.54M
Revenue (ttm)	226.73M
Net Income (ttm)	-86.19M
Shares Out	20.79M
EPS (ttm)	-4.19
PE Ratio	n/a
Forward PE	9.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,550
Open	15.99
Previous Close	16.09
Day's Range	15.80 - 16.45
52-Week Range	7.08 - 20.90
Beta	0.72
Analysts	Strong Sell
Price Target	12.00 (-24.74%)
Earnings Date	Oct 29, 2025

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Apr 1, 1993
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRN
• Website: https://www.amarincorp.com

Financial Performance

In 2024, Amarin Corporation's revenue was $228.61 million, a decrease of -25.51% compared to the previous year's $306.91 million. Losses were -$82.18 million, 39.0% more than in 2023.

Analyst Summary

According to one analyst, the rating for AMRN stock is "Strong Sell" and the 12-month stock price target is $12.0.

Price Target

$12.0

(-24.74% downside)

Analyst Consensus: Strong Sell